What’s the current market cap for Novartis stock?

Novartis (NVS) has a market cap of $269bn as of June 06, 2026.

What is the P/E ratio for Novartis stock?

The price to earnings (P/E) ratio for Novartis (NVS) stock is 21.26 as of June 06, 2026.

Does Novartis stock pay dividends?

Yes, the Novartis (NVS) stock pays dividends to shareholders. As of June 06, 2026, the dividend rate is $3.08116 and the yield is 2.08%. Novartis has a payout ratio of 64.15% on a trailing twelve-month basis.

When is the next Novartis dividend payment date?

The next Novartis (NVS) dividend payment date is unconfirmed.

What is the beta indicator for Novartis?

Novartis (NVS) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Novartis stock | $NVS Share Price

13:30

15:10

16:45

18:25

20:00

About Novartis

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Ticker

$NVS

Sector

Health

Primary listing

NYSE

Employees

75,267

Headquarters

Basel, Switzerland

Website

www.novartis.com

Novartis Metrics

BasicAdvanced

$269bn

21.26

$6.98

0.49

$3.08

2.08%

What the Analysts think about Novartis

Analyst ratings (Buy, Hold, Sell) for Novartis stock.

Bulls say / Bears say

Despite a 42% drop in Entresto sales, strong demand for the breast cancer drug Kisqali and multiple sclerosis treatment Kesimpta helped Novartis achieve low single-digit net sales growth in Q1 2026. (Reuters)

Novartis agreed to acquire SNV4818, a selective PI3Kα inhibitor for HR+/HER2– breast cancer, from Synnovation Therapeutics for up to $3 billion, strengthening its oncology pipeline. (Reuters)

The planned radioligand therapy manufacturing site in Texas will expand Novartis's US production capacity for its growing radioligand therapy portfolio, supporting faster product supply and potential cost efficiencies. (Reuters)

Sales of blockbuster heart drug Entresto plunged 42% to $1.31 billion in Q1 2026 following the entry of generics, significantly weighing on revenue. (Reuters)

Core operating income declined 12% to $4.9 billion in Q1 2026, missing analyst expectations as generic competition and increased R&D investment pressured margins. (Reuters)

Novartis forecast its first annual decline in operating profit in over a decade for 2026 due to the largest-ever patent expiry cycle, indicating near-term earnings headwinds. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

Novartis Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Novartis Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVS

Capital at risk

Market closedADR

Upcoming events

No upcoming events